🧪 When a Pharmaceutical Company Builds Its Own Radionuclide Production Capability

2026-08-31

An LBT 11 MeV medical cyclotron is supporting radiopharmaceutical R&D at a pharmaceutical company in Chengdu, China, where the system is frequently operated to meet ongoing research needs.

⚛️ Dedicated primarily to radiopharmaceutical development, the platform provides the company with flexible, in-house radionuclide production capability for its R&D programs.

🔬 One of its key applications is Cu-64 production using a solid target system, supporting the development of novel molecular imaging agents and theranostic radiopharmaceuticals.

🏗️ The cyclotron adopts a non-self-shielded configuration and is installed in a purpose-designed bunker. LBT’s engineering team provided technical support for the radiation shielding and maze layout, helping the customer integrate the cyclotron with the facility from the project design stage.

⚙️ Today, the cyclotron and solid target system are used frequently as part of the company’s R&D workflow, supporting repeated irradiation and radionuclide production for radiochemistry and new drug development.

🚀 From cyclotron installation and facility engineering to radionuclide production, LBT provides integrated support for the evolving needs of radiopharmaceutical R&D.